Rtw Investments Adds $20M in Dianthus Therapeutics, Inc. ($DNTH)
Rtw Investments added 248,063 shares of DNTH, valued at $20.4 million.
Key Points
- Rtw Investments initiated a new position in DNTH, acquiring 248,063 shares valued at $20.4 million.
- Shares of DNTH traded near $82.07, with a market presence among major institutional investors.
- Analysts like Wedbush and Wolfe Research have set positive price targets for DNTH, reflecting strong market interest.
Rtw Investments has taken a new position in DNTH, acquiring 248,063 shares. This move, valued at about $20.4 million, was disclosed in a recent 13F filing with the SEC. The shares were bought at a cost basis of $62.96 each, marking this as a significant new entry into DNTH.
What Changed in Rtw Investments' DNTH Position
Rtw Investments' new stake in DNTH stands at 248,063 shares, valued at approximately $20.4 million. This represents a fresh investment since the fund previously held no shares in the company.
Other Institutional Activity in DNTH
Several other major funds have been active in DNTH. FMR LLC increased its holdings by 1,336,357 shares, ending with 7,767,686 shares valued at around $651.9 million. BlackRock, Inc. also boosted its stake significantly, adding 1,260,467 shares to hold a total of 3,175,703 shares worth $266.5 million. RA Capital Management, L.P. added 1 million shares, resulting in 2,611,733 shares valued at $219.2 million. Wellington Management Group LLP and Fairmount Funds Management LLC also increased their positions by 92,593 and 400,000 shares, respectively.
DNTH Stock Snapshot
Shares of DNTH are trading near $82.07. The stock has attracted attention from large institutional investors, as reflected in recent filings. While further financial details such as market cap and P/E ratio are not provided, the significant institutional interest suggests confidence in the company's potential.
Insider Buying and Selling at Dianthus Therapeutics, Inc.
On June 1, 2026, Simrat Randhawa, EVP and Head of R&D at DNTH, sold 26,530 shares at an average price of $90.62 under a planned sale. On the same day, Randhawa also purchased 26,530 shares at $18.85. Additionally, Simon Read and Jonathan Violin each bought 6,090 shares on May 21, 2026.
Analysts Set New Price Targets
Analyst firms have shown a positive outlook for DNTH. On May 6, 2026, Wedbush maintained a 'buy' rating with a $105 price target. Wolfe Research initiated coverage on April 9, 2026, with a 'buy' rating and a $98 target. Wells Fargo also initiated coverage with a 'buy' rating and a $135 target on March 19, 2026. The consensus indicates a strong buy sentiment with an average target price reflecting optimism.
About DNTH
DNTH operates in an unspecified sector and industry, focusing on innovative solutions and services. While specific details about its operations and leadership are not provided, the company has attracted significant investment interest from major institutional investors.
Bottom Line
Rtw Investments' new position in DNTH highlights the company's growing appeal among institutional investors. This 13F filing provides a backward-looking glimpse into Rtw Investments' strategy as of the reporting period. With strong analyst support and active insider trading, DNTH remains a company to watch in the market.
See Also
This instant news alert was generated by automated narrative technology and financial data from Trueearnings and public regulatory filings. It is for informational purposes only and is not financial advice.